CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.3163
-0.0038 (-1.17%)
Sep 5, 2025, 3:59 PM EDT
CytoDyn Employees
CytoDyn had 13 employees as of May 31, 2025. The number of employees increased by 4 or 44.44% compared to the previous year.
Employees
13
Change (1Y)
4
Growth (1Y)
44.44%
Revenue / Employee
n/a
Profits / Employee
$174,000
Market Cap
396.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 13 | 4 | 44.44% |
| May 31, 2024 | 9 | -3 | -25.00% |
| May 31, 2023 | 12 | -11 | -47.83% |
| May 31, 2022 | 23 | -1 | -4.17% |
| May 31, 2021 | 24 | 5 | 26.32% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| HealthLynked | 20 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Longduoduo Company | 49 |
CytoDyn News
- 3 days ago - CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 10 days ago - CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 weeks ago - CytoDyn files $100M mixed securities shelf - Seeking Alpha
- 2 months ago - CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab - GlobeNewsWire
- 2 months ago - CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer - GlobeNewsWire
- 3 months ago - A Penny Stock To Watch In Challenging Cancer Space - Benzinga
- 4 months ago - CytoDyn Releases ESMO Breast Cancer Meeting Poster - GlobeNewsWire
- 4 months ago - CytoDyn highlights potential of lead drug against solid tumors with new data - Seeking Alpha